SCHEMBL6255381

SCHEMBL6255381

NC(CC1=CCCCC1)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 2/20 0.48
GRIA4 P48058 2/20 0.48
GRIK5 Q16478 2/20 0.48
GRIA3 P42263 1/20 0.48
SLC7A5 Q01650 3/20 0.44
PTGS1 P23219 2/20 0.43
ALPI P09923 1/20 0.43
PKM P14618 1/20 0.43
XIAP P98170 1/20 0.43
GRIK1 P39086 2/20 0.42
GRIA2 P42262 1/20 0.42
GRIK3 Q13003 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TYR P14679 5/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KDM4E B2RXH2 1/20 0.41
USP2 O75604 1/20 0.41
EGFR P00533 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4757741 1.00 GRIA1 (0.48) GRIA1GRIA4GRIK5GRIA3SLC7A5
SCHEMBL5298700 0.98 GRIA1 (0.47) GRIA1GRIA4GRIK5GRIA3SLC7A5
SCHEMBL615017 0.95 GRIA1 (0.52) GRIA1GRIA4GRIK5GRIA3SLC7A5
SCHEMBL939749 0.95 GRIA1 (0.52) GRIA1GRIA4GRIK5GRIA3SLC7A5
SCHEMBL14485771 0.95 GRIA1 (0.52) GRIA1GRIA4GRIK5GRIA3SLC7A5
Benzoquinone SCHEMBL23630290 0.92 GRIA1 (0.46) GRIA1GRIA4GRIK5GRIA3SLC7A5
SCHEMBL612974 0.81 GRIA1 (0.43) GRIA1GRIA4GRIK5GRIA3
SCHEMBL9512449 0.80 ALDH1A1 (0.43) ALDH1A1MAPTL3MBTL1NPSR1TAAR1
SCHEMBL9512439 0.80 ALDH1A1 (0.43) ALDH1A1MAPTL3MBTL1NPSR1TAAR1
Hydrochloric Acid SCHEMBL11881163 0.79 KDM4E (0.46) ALDH1A1MAPTKDM4EHSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158179-A1 RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF RAYZEBIO, INC. 2023-05-25 US disclosed
US-20230158179-A1 RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF RAYZEBIO, INC. 2023-05-25 US disclosed
US-20230090247-A1 MOLECULES TARGETING RAS PROTEIN VIB VZW (BE) 2023-03-23 US disclosed
EP-4106787-A1 MOLECULES TARGETING RAS PROTEIN Aelin Therapeutics (BE) 2022-12-28 EP disclosed
US-10017773-B2 HSF-like transcription factor, TBF1, is a major molecular switch for growth-to-defense transition in plants DUKE UNIVERSITY (US) 2018-07-10 US disclosed
EP-1134283-B1 Method for producing L-Phenylalanine AJINOMOTO KK (JP) 2005-09-14 EP disclosed
US-6350596-B2 Method for producing L-phenylalanine AJINOMOTO CO., INC. (JP) 2002-02-26 US disclosed
US-20010044139-A1 Method for producing L-phenylalanine AJINOMOTO CO., INC. (JP) 2001-11-22 US disclosed
EP-1134283-A1 Method for producing L-Phenylalanine Ajinomoto Co., Inc. (JP) 2001-09-19 EP disclosed
EP-0138526-B1 METHOD OF PRODUCING L-PHENYLALANINE BY FERMENTATION, AND BACTERIA THEREFOR AJINOMOTO CO., INC. (JP) 1989-04-26 EP disclosed
US-4766110-A INHIBITS ANGIOTENSIN CONVERTING ENZYME, HYPOTENSIVE AGENTS RYAN JAMES W (US) 1988-08-23 US disclosed
US-4591562-A GENETIC ENGINEERING, INCORPORATING RECOMBINANT PLASMID DNA DERIVEDFROM BACILLUS AJINOMOTO COMPANY INCORPORATED (JP) 1986-05-27 US disclosed
EP-0073143-B1 NOVEL COMPLEX AMIDO AND IMIDO DERIVATIVES OF CARBOXYALKYL PEPTIDES AND THIOETHERS AND ETHERS OF PEPTIDES Ryan, James Walter (US) 1985-11-21 EP disclosed
US-4407952-A OF GENETICALLY ENGINEERED ESCHERICHIA AJINOMOTO COMPANY INCORPORATED (JP) 1983-10-04 US disclosed
US-4403033-A Method for producing L-phenylalanine by fermentation AJINOMOTO COMPANY INCORPORATED (JP) 1983-09-06 US disclosed
EP-0073143-A2 Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides Ryan, James Walter (US) 1983-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230158179-A1 RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF PAICS, LNPEP, DNPEP GRIA1 2608/4885GRIA4 3341/4885GRIK5 2808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.